{
      "brief_title": [
            "study",
            "evaluate",
            "safety",
            "raptiva",
            "adult",
            "plaque",
            "psoriasis",
            "previously",
            "enrol",
            "study"
      ],
      "brief_summary": [
            "open",
            "label",
            "multicenter",
            "study",
            "design",
            "evaluate",
            "safety",
            "tolerability",
            "efalizumab",
            "administer",
            "subcutaneously",
            "weekly",
            "dose",
            "subject",
            "plaque",
            "psoriasis",
            "previously",
            "participate",
            "study"
      ],
      "condition": [],
      "intervention_type": [
            "Drug"
      ],
      "intervention_name": [
            "Raptiva (efalizumab)"
      ],
      "criteria": [
            "inclusion",
            "criterion",
            "sign",
            "inform",
            "consent",
            "previous",
            "participation",
            "study",
            "woman",
            "childbearing",
            "potential",
            "continue",
            "use",
            "acceptable",
            "method",
            "contraception",
            "duration",
            "study",
            "exclusion",
            "criterion",
            "medical",
            "condition",
            "judgment",
            "investigator",
            "would",
            "jeopardize",
            "subject",
            "safety",
            "follow",
            "exposure",
            "efalizumab"
      ],
      "gender": "All",
      "minimum_age": [],
      "maximum_age": [],
      "healthy_volunteers": "No",
      "keyword": [
            "moderate",
            "severe",
            "plaque",
            "psoriasis"
      ],
      "mesh_term": [],
      "id": "NCT00096603"
}